NRC	FO	RM	374
-----	----	----	-----

## U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 4 PAGES
Amendment No. 63
Corrected Copy

## **MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

and to ar	iny conditions specified below.			Ti- considerati						
Licensee  1. St. Joseph Health System LLC d/b/a St. Joseph Hospital				In accordance with the application dated  March 21, 2011,						
				3. License number 13-00418-02 is renewed in its entirety to read as follows:						
2. 700	Broadway		. !	4. Expiration date September 30, 2021						
Fort	t Wayne, IN 46802			5. Docket No. 030 Reference No.	-0158	<i>i</i> 1				
	product, source, and/or special clear material	7. Ch	nemical and/o	or physical form	8.	pos	ximum amount that licensee may ssess at any one time under this ense			
Α.	Any byproduct material permitted by 10 CFR 35.100	A.	Any			A.	As needed			
В.	Any byproduct material permitted by 10 CFR 35.200	В.	Any			B.	As needed			
C.	Any byproduct material permitted by 10 CFR 35.300	C.	Any			C.	1000 Millicuries			
D.	Any byproduct material permitted by 10 CFR 35.500			ource ce/Gammatron, lel OS-213A)		D.	300 millicuries per source and 300 millicuries total			
9. A	Authorized use:									
А	A. Any uptake, dilution and excre	etion stu	ıdy permitt	ed by 10 CFR 35	5.100.					
В	3. Any imaging and localization s	study pe	ermitted by	10 CFR 35.200.			·			
С	C. Any diagnostic study or therap	oy proc€	dure perm	nitted by 10 CFR	35.30	10.				

## CONDITIONS

- 10. Licensed material may be used or stored only at the licensee's facilities located at 700 Broadway, Fort Wayne, Indiana.
- 11. The Radiation Safety Officer for this license is Dakshesh Patel, M.D.

D. For storage only incident to disposal.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE	2	of	4	PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET		License Number 13-00418-02	-				
	Docket or Reference Number 030-01581	•					
		Amendment No. 63					
		Corrected Copy					

- 12. Licensed material is only authorized for use by, or under the supervision of:
  - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
  - B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
Brett Hagedorn, M.D.	10 CFR 35.100 and 35.200.
John Pasalich, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
Stephen R. Phillip, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
Marc Thomas, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
David Sorg, M.D.	10 CFR 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).
Diane D. Daly, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
Frederick N. Vandeman, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 35.500.
Christopher Kowalski, M.D.	10 CFR 35.100 and 35.200.
Joseph R. DeCamp, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 35.500.
John L. Bormann, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
Michael E. Parker, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
Andre B. Stovall, M.D.	10 CFR 35.100 and 35.200.
Pamela Lee Strange, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
John Rock, M.D.	10 CFR 35.100 and 35.200.
Richard P. Stephens, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
James C. Wehrenberg, M.D.	10 CFR 35.100 and 35.200.
James A. Arata, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
David B. Janizek, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.
Christine Anne Tremper, M.D.	10 CFR 35.100 and 35.200.
Randall J. Phillips, M.D.	10 CFR 35.100, 35.200, 35.300, and 35.500.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE	3	of	4	PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 13-00418-02						
	Docket or Reference Numbe 030-01581	r					
	Amendment No. 63 Corrected Copy						

Authorized Users	<u>Material and Use</u>
John R. Kim, M.D.	10 CFR 35.100, 35.200, 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries), and 35.500.
Richard Sibley, M.D.	10 CFR 35.100 and 35.200.
Dakshesh Patel, M.D.	10 CFR 35.100 and 35.200.
Shilpa Kashyap, M.D.	10 CFR 35.100 and 35.200.
H. Steven Beyer, M.D.	10 CFR 35.300 (limited to the oral administration of sodium iodide I-131).
Eric V. Heatwole, M.D.	10 CFR 35.100 and 35.200.
Shawn Johnson, M.D.	10 CFR 35.100, 35.200, and 35.300.
Sandeep S. Ahluwalia, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131).
John C. Lacunza, M.D.	10 CFR 35.100 and 35.200.
Linda Gould Hippenhammer, M.D.	10 CFR 35.100, 35.200, and 35.300.
Daniel Branam, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).
Jonathon Berger, M.D.	10 CFR 35.100 and 35.200.
Eugene Shih, M.D.	10 CFR 35.100 and 35.200.
John H. Arnett, M.D.	10 CFR 35.100, 35.200, and 35.500.
Jeffery J. Freeman, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide I-131).

- 13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
- 14. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.
- 15. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE	4	of	4	PAGES
	·	License Number 13-00418-02					
	MATERIALS LICENSE SUPPLEMENTARY SHEET	Docket or Reference Number 030-01581	r				
		Amendment No. 63					
		Corrected Copy					

- 16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
  - A. Application dated March 21, 2011; and
  - B. Letter dated September 22, 2011.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date JAN 0 6 2012

Sara A.B. Forster Materials Licensing Branch

Region III